Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4303-4308

  Park, In Ja ^a   Choi, Gyu Seog ^a   Jun, Soo Han ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

CA19 9; Peritoneal recurrence; Preoperative; Recurrence

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ASSESSMENT; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERITONEUM METASTASIS; POSTOPERATIVE PERIOD; PREDICTIVE VALIDITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD;

EID: 71949109778     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chapman MA, Buckley D, Henson DB and Armitage NC: Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer 78: 1346-1349, 1998. (Pubitemid 28495248)
2. Morales-Gutierrez C, Vegh I, Colina F, Gomez-Camara A, Ignacio Landa J, Ballesteros D, Carreira PE and Enriquez-De-Salamanca R: Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination. Cancer 86: 1675-1681, 1999. (Pubitemid 29513035)
3. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U and Lamerz R: Multivariate analysis of the prognostic value of CEA and CA19-9 serum levels in colorectal cancer. Anticancer Res 20: 5195-5198, 2000. (Pubitemid 32319106)
4. Gasser M, Gerslauer C, Grimm M, Bueter M, Lebedeva T, Lutz J, Maeder U, Ribas C, Ribas C, Nichiporuk E, Thalheimer A, Heemann U, Thiede A, Meyer D and Waaga-Grasser AM: Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer. Ann Surg Oncol 14: 1272-1284, 2007. (Pubitemid 46536803)
5. Gobbi PG, Valentino F, Berardi E, Tronconi C, Brugnatelli S, Luinetti O, Moratti R and Corazza GR: New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer 29: 328-334, 2008. (Pubitemid 351161236)
6. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H and Arisawa K: Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology 50: 696-699, 2003. (Pubitemid 36613383)
7. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
8. Filella X, Molina R, Grau JJ, Piqué JM, Garcia-Valdecasas JC, Astudillo E, Biete A, Bordas JM, Novell A, Compo E and Ballesta AM: Prognostic value of CA19.9 levels in colorectal cancer. Ann Surg 216: 55-59, 1992.
9. Diez M, Cerdán FJ, Pollán M, Maestro ML, Ortega MD, Martínez S, Moreno G and Balibrea JL: Prognostic significance of preoperative serum CA19.9 assay in patients with colorectal carcinoma. Anticancer Res 14: 2819-2825, 1994.
10. Liska V, Holubec L Jr, Treska V, Skalicky T, Sutnar A, Komunda S, Pesta M, Finek J, Rousarova M and Topolcan O: Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases. Anticancer Res 27: 2861-2864, 2007. (Pubitemid 47228011)
11. Ueda T, Shimada E and Urakawa T: The clinicopathologic features of serum CA19-9-positive colorectal cancers. Surg Today 24: 518-525, 1994. (Pubitemid 24235304)
12. Franchi F, Pastore C, Izzo P and Calio E: CA19-9 in the monitoring of colorectal cancer after surgery. Med Oncol 18: 237-238, 2001. (Pubitemid 33097352)
13. Levy M, Visokai V, Lipska L and Topolcan O: Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 55: 138-142, 2008.
14. Nicolini A, Caciagli M, Zampieri F, Ciampalini G, Carpi A, Spisni R and Colizzi C: Usefulness of CEA, TPA, GICA, CA72.4, and CA195 in the diagnosis of primary colorectal cancer and at its relapse. Cancer Detect Prev 19: 183-195, 1995.
15. Filella X, Molina R, Piqué JM, Garcia-Valdecasas JC, Grau JJ, Novell F, Astudillo E, de Lacy A, Daniels M and Ballesta AM: Use of CA19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumour Biol 15: 1-6, 1994. (Pubitemid 24122938)
16. Griesenberg D, Nurnberg R, Bahlo M and Klapdor R: CEA, TPS, CA19-9 and CA72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 19: 2443-2450, 1999. (Pubitemid 29392391)
17. Plebani M, De Paoli M, Basso D, Roveroni G, Giacomini A, Galeotti F and Corsini A: Serum tumor markers in colorectal cancer staging, grading, and follow-up. J Surg Oncol 62: 239-244, 1996. (Pubitemid 26262345)
18. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C and Topolcan O: Tumor markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 43: 1348-1360, 2007. (Pubitemid 46874070)
19. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ and Haglund C: Serum HCG beta, CA72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 101: 545-548, 2002.
20. Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N and Shibata N: Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum 47: 227-232, 2004.
21. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS and Chang SC: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124: 169-174, 2005.
22. Lindmark G, Bergstrom R, Pahlman L and Glimelius B: The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 71: 1090-1094, 1995.
23. Carpelan-Holmstrom M, Haglund C, Lundin J, Jarvinen H and Roberts P: Pre-operative serum levels of CA242 and CEA predict outcome in colorectal cancer. Eur J Cancer 32A: 1156-1161, 1996. (Pubitemid 26231796)
24. Nakayama T, Watanabe M, Teramoto T and Kitajima M: Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res 17: 1379-1382, 1997. (Pubitemid 27182468)
25. Holubec L, Topolcan O, Pikner R, Pecen L, Vaclavickova J, Wirthova M, Molacek J, Stieber P, Holdenrieder S, Sen LH and Finek J: The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. Anticancer Res 20: 5237-5244, 2000.
26. Spila A, Ferroni P, Cosimelli M, D'Alessandro R, Abbolito MR, Mariotti S, Aloe S, Carone MD, Graziano F, Tedesco M, Martini F, Mancini R, Stigliano V, Roselli M and Guadagni F: Comparative analysis of CA242 and CA19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Anticancer Res 21: 1263-1270, 2001.
27. Novis BH, Gluck E, Thomas P, Steele GD, Zurawski VR Jr, Stewart R, Lavin PT and Zamcheck N: Serial levels of CA19-9 and CEA in colonic cancer. J Clin Oncol 4: 987-993, 1986. (Pubitemid 16080955)
28. Szymendera JJ, Nowacki MP, Kozlowicz-Gudzinska I and Kowalska M: Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum 25: 895-899, 1985. (Pubitemid 16191023)
29. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA and Tangen C: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270: 943-947, 1993. (Pubitemid 23244732)
30. Peng JJ, Cai SJ, Lu HF, Cai GX, Lian P, Guan ZO, Wang MH and Xu Y: Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers. World J Gastroenterol 13: 3009-3015, 2007. (Pubitemid 47028893)
31. Yang SH, Lin JK, Lai CR, Chen CC, Li AF, Liang WY and Jiang JK: Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 87: 167-173, 2004. (Pubitemid 39167383)
32. Dabelsteen E: Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 179: 358-369, 1996. (Pubitemid 26276103)
33. Martini F, Guadagni F, Lenti L, D'Alessandro R, Aloe S, Roselli M, Gazzaniga PP and Ferroni P: CA19-9 monosialoganglioside content of human colorectal tumor cells correlates with tumor cell-induced platelet aggregation. Anticancer Res 20: 1609-1614, 2000. (Pubitemid 30628173)
34. Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B and Juhl H: Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 227: 372-379, 1998. (Pubitemid 28131018)